Intellia Therapeutics (NTLA) PT Lowered to $172 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Geulah Livshits lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $172.00 (from $177.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
